MartinsFSofiyaLSykiotisGP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563-580. doi:10.1038/s41571-019-0218-0
2.
PooleMSchwartzRALambertWCAlhatemA.To treat or not to treat: PD-L1 inhibitor-induced keratoacanthoma and squamous cell carcinoma. Arch Dermatol Res. 2023;315(4):903-915. doi:10.1007/s00403-022-02468-3
3.
FeldsteinSIPatelFLarsenLKimEHwangSFungMA.Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after programmed cell death 1 inhibition with nivolumab. J Eur Acad Dermatol Venereol. 2018;32(2):e58-e59. doi:10.1111/jdv.14503
4.
FradetMSibaudVTournierE, et al. Multiple keratoacanthoma-like lesions in a patient treated with pembrolizumab. Acta Derm Venereol. 2019;99(13):1201-1302. doi:10.2340/00015555-3301
5.
GuidaMStrippoliSMauleM, et al. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. ESMO Open. 2021;6(2):100064. doi:10.1016/j.esmoop.2021.100064
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
